U.S. Stock News

Fastly, Inc. previously reported first-quarter 2026 results with revenue rising to US$173.02 million from US$144.47 million a year earlier, while narrowing its net loss to US$20.52 million and cutting basic loss per share from US$0.27 to US$0.13. The quarter highlighted especially strong momentum in higher-margin security and compute products, which delivered record contributions and underpinned Fastly’s decision to raise full-year 2026 revenue and profit guidance. We’ll now examine how...

Oppenheimer Holdings Inc. reported first-quarter 2026 results, with revenue rising to US$445.1 million from US$367.83 million a year earlier, but swinging from net income of US$30.66 million to a net loss of US$20.58 million, and moving from basic earnings per share of US$2.93 to a basic loss of US$1.93. Despite this shift to a loss, the company also announced a quarterly dividend of US$0.20 per share payable on May 29, 2026, indicating continued cash returns to shareholders even as...

American Bitcoin stock moves after recent trading swing American Bitcoin (ABTC) has drawn fresh attention after a recent trading swing, with the stock closing at US$1.16 and carrying a market value of about US$1.33b in the US listed Bitcoin mining space. See our latest analysis for American Bitcoin. The recent 7.2% one-day share price decline comes after a 33.1% 30-day share price return, while the year-to-date share price return of 34.83% suggests momentum has been fading over a longer...

In late April 2026, O-I Glass, Inc. reported first-quarter 2026 results showing sales of US$1,540 million, down from US$1,567 million a year earlier, and a wider net loss of US$73 million versus US$16 million, with basic and diluted loss per share from continuing operations both at US$0.48 compared to US$0.10 previously. This sharp increase in quarterly loss, despite only a modest sales decline, raises questions about cost pressures and profitability trends across O-I Glass's...

Kimco Realty reported past first-quarter 2026 results showing year-over-year growth, with revenue rising to US$558.02 million and net income to US$164.9 million, while also declaring quarterly common and preferred dividends. Alongside these results, management raised full-year 2026 net income guidance per diluted share, signaling increased confidence in the company’s earnings outlook and cash flow visibility. Next, we’ll examine how Kimco’s higher full-year net income guidance influences its...

ImmunityBio (IBRX) is under close watch after an FDA warning letter on allegedly misleading promotional claims for Anktiva and a series of class action lawsuits, even as the company reports recent revenue and global approval figures. See our latest analysis for ImmunityBio. After touching a 1 day share price return of negative 7.4% following the FDA warning letter and class action headlines, ImmunityBio still sits at US$7.76 with a year to date share price return of 284.16% and a 1 year total...

Wondering if Fox at around US$62.69 is priced for opportunity or already reflects the story? This piece walks through the key numbers to help you frame that question clearly. The stock has seen mixed recent returns, with a 1.3% decline over the last week, a 5.1% gain over the last 30 days, a 15.0% decline year to date and a 25.5% return over the last year, alongside longer term returns of 112.3% over three years and 72.6% over five years. Recent market interest has been shaped by ongoing...

If you are wondering whether American States Water at around US$76.84 is priced fairly or offering value, it helps to step back and look at what the recent share performance and fundamentals are signaling. Over the short term the stock is up 2.1% over the last week and is roughly flat over the past month with a 0.1% decline, while year to date it is up 6.3% and the 1 year return sits at a 1.8% decline. These moves come as investors continue to react to company specific developments and the...

Halozyme Therapeutics (NasdaqGS:HALO) has entered a new global collaboration with GSK to apply its ENHANZE technology to subcutaneous delivery of multiple oncology products. The agreement includes development of subcutaneous formulations for antibody drug conjugates, expanding ENHANZE into a new class of cancer therapies. The collaboration introduces additional potential royalty streams tied to future use of ENHANZE across GSK’s oncology portfolio. Halozyme Therapeutics, trading at $65.19,...

Oculis Holding secured a formal Special Protocol Assessment from the FDA for its pivotal Phase 3 PIONEER-1 trial of Privosegtor in optic neuritis. The FDA agreement confirms that the PIONEER-1 trial design is adequate to support a potential future NDA submission. In parallel, new findings from the DME AWARE study support further development of OCS-01 eye drops for diabetic macular edema. These updates arrive with NasdaqGM:OCS trading at $31.09, with the stock up 13.1% over the past week and...

RPM International (RPM) drew fresh attention after reporting third quarter fiscal 2026 earnings and sales that exceeded expectations, alongside guidance regarding sales and adjusted EBIT. See our latest analysis for RPM International. The share price has eased back recently, with a 1 month share price return of 4.84% but a 90 day share price return decline of 13.30%, while the 1 year total shareholder return decline of 6.79% contrasts with a 3 year total shareholder return of 32.76%. This...

Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or if the easy gains are behind it. The stock has pulled back 18.8% over the last week and 22.5% over the last month, yet it still shows a 15.7% gain year to date and a 96.6% return over the past year. These sharp moves are drawing attention back to what is already priced into Phibro Animal Health and how much of its story is reflected in the current share price. Ongoing interest...

Recent performance puts Apple Hospitality REIT in focus Apple Hospitality REIT (APLE) has drawn fresh attention after a one-month return of about 19% and a gain of roughly 14% over the past three months, prompting investors to reassess the hotel-focused REIT’s recent momentum. See our latest analysis for Apple Hospitality REIT. At a share price of $13.89, Apple Hospitality REIT’s recent 19.43% 1 month share price return and 15.17% year to date share price return contrast with a steadier 1...

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...

If you are wondering whether Bruker stock is priced attractively or already reflects its prospects, the recent share moves make that question especially timely. The stock last closed at US$43.73, with returns of 19.1% over the past week and 19.3% over the past month, compared with an 8.5% gain over the past year and longer term returns over 3 and 5 years that have been negative. These shorter term gains come after a period where investors have been reassessing many life sciences and tools...

Recursion Pharmaceuticals (RXRX) is back in focus after a busy Q1 2026, with fresh clinical data for REC-1245, first patient dosing for REC-4539, and FDA engagement around REC-4881 following promising Phase 2 results. See our latest analysis for Recursion Pharmaceuticals. The clinical updates and Q1 results have come with pressure on the stock, with a 30 day share price return of 2.51% contrasting with a 1 year total shareholder return decline of 25.51%, which points to fading longer term...

Wondering if Agilent Technologies at US$118.65 is offering solid value or just fair pricing right now? This article breaks down what the current market price might be implying. The stock is up 2.7% over the last week and 4.2% over the last month, even though the year to date return stands at a 14.0% decline and the 1 year return is 10.0%. Taken together, these figures provide a mixed picture of sentiment and recent momentum. Recent coverage has focused on how Agilent Technologies fits into...

For investors considering whether Waste Connections at around US$153.57 represents fair value or a potential opportunity, this article explains what the current price may indicate. The stock has come under recent pressure, with a 6.8% decline over the last week, a 6.4% decline over the last month, and a 20.8% decline over the last year. This comes despite 3 year and 5 year returns of 9.3% and 32.4% respectively. Recent coverage has examined how the stock's pullback compares with the broader...

Digi International acquired Jolt Software and Particle Industries, reshaping its Internet of Things (IoT) offering. The company reports that these deals, combined with organic growth, have lifted annual recurring revenue (ARR) by 50%. Management highlights strong cash flow as a key support for integrating these acquisitions into the existing business. Digi International (NasdaqGS:DGII) is drawing fresh attention as it leans harder into IoT platforms and recurring software revenue. The stock...

If you are wondering whether Builders FirstSource at around US$79.41 is starting to look interesting again, the key question is how its current price compares with a fair estimate of value. The stock has inched up 0.4% over the last week and 0.6% over the last month, but that sits against a much tougher backdrop, with returns of a 24.1% decline year to date and a 28.5% decline over the past year. These moves come as the market continues to reassess building and construction related stocks,...

Main Street Capital (MAIN) has wrapped up FY 2025 with fourth quarter revenue of US$145.5 million and basic EPS of US$1.46. This sets the tone for a year in which trailing twelve month revenue reached US$566.4 million and EPS was US$5.52. Over recent periods, the company has reported quarterly revenue ranging between US$137.0 million and US$145.5 million, while basic EPS has moved between US$1.31 and US$1.46. Trailing net income for the year was US$493.4 million, as investors weigh those...

Earlier this week, IREN Limited announced it had signed a five-year AI infrastructure cloud services contract with NVIDIA worth about US$3.40 billion, under which IREN will supply managed GPU cloud services using Blackwell systems across roughly 60MW at its Childress, Texas data centers. Alongside this cloud deal, NVIDIA received a five-year right to buy up to 30 million IREN shares at US$70 each, tying IREN’s shift from Bitcoin mining toward large-scale AI infrastructure directly to a major...

In the first quarter ended March 31, 2026, Revolve Group, Inc. reported sales of US$342.88 million, net income of US$14.35 million, and diluted earnings per share from continuing operations of US$0.20, all higher than a year earlier. This past-quarter improvement in both revenue and profitability gives investors fresh data to reassess how Revolve’s growth investments may be translating into earnings power. With first-quarter revenue and net income both higher year over year, we’ll now...

Wondering if Ball at around US$58.41 is offering fair value or potential mispricing? This article breaks down what the current share price might be implying about the stock. The stock is up 9.5% year to date and 14.5% over the last year. However, there have been shorter term pullbacks, with a 4.4% decline over the past week and a 1.4% decline over the past month. Recent coverage has focused on Ball's position in materials and packaging, as investors reassess how companies in this space might...